425: HSPT & SL BIO Announce New Directors for Combined Entity

Horizon Space Acquisition II Corp. and SL BIO Ltd. announced the addition of two independent director nominees and updated beneficial ownership ahead of their business combination meeting.

Summary

• Horizon Space Acquisition II Corp. (HSPT) and SL BIO Ltd. are supplementing their definitive proxy statement for the proposed business combination.
• Two new independent director nominees, Joseph Levinson and Qian (Hebe) Xu, have been added to the anticipated board of directors for the combined entity, SL Science Holding Limited (PubCo).
• Joseph Levinson brings over 25 years of experience in cross-border issues for U.S.-listed foreign companies and accounting, holding a Certified Public Accountant (CPA) license.
• Qian (Hebe) Xu has over 15 years of experience in financial markets, specializing in US-China cross-border transactions, and currently serves as an independent director for HSPT and Hongli Group Inc. (Nasdaq: HLP).
• The beneficial ownership of PubCo Ordinary Shares immediately following the business combination has been updated to reflect the new nominees.
• William Wang, the anticipated CEO, Director, and Chairman, will beneficially own 333,832,129 PubCo Ordinary Shares, representing 58.9% in a no-redemption scenario and 59.6% in a maximum-redemption scenario.
• Qian (Hebe) Xu will beneficially own 20,000 PubCo Ordinary Shares, converted from HSPT founder shares.
• The Business Combination Meeting remains scheduled for February 12, 2026, at 9:00 a.m. Eastern Time, with a redemption deadline of February 10, 2026, at 5:00 p.m. Eastern Time.
• SL Link Co., Ltd., controlled by Mr. Wang, acquired 30,000 ordinary shares of SL Bio on January 5, 2026, at US$66.67 per share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive procedural update, strengthening the combined entity's governance with experienced independent directors, which is favorable for investor confidence. The unchanged meeting schedule indicates smooth progress towards the business combination.

Positives

• The addition of two experienced independent directors, Joseph Levinson and Qian (Hebe) Xu, enhances the corporate governance and financial oversight capabilities of the combined entity.
• Joseph Levinson's extensive background in accounting and managing cross-border issues for U.S.-listed foreign companies is a valuable asset.
• Qian (Hebe) Xu's expertise in financial markets and US-China cross-border transactions strengthens the board's strategic and financial acumen.
• The business combination meeting schedule remains unchanged, indicating progress towards closing the transaction.

Risks

• SL Bio's or the combined company's limited operating history.
• The ability of SL Bio or the combined company to identify and integrate acquisitions.
• General economic and market conditions impacting demand for the products of SL Bio or the combined company.
• The inability to complete the proposed Business Combination.
• The inability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by the amount of cash available following any redemptions by HSPT's shareholders.
• The ability to meet stock exchange listing standards following the consummation of the proposed Business Combination.
• Costs related to the proposed Business Combination.
• The possibility that the proposed Business Combination does not close, including due to the failure to receive required security holder approvals, or the failure of other closing conditions.

Future Outlook

The combined company, SL Science Holding Limited (PubCo), expects its executive compensation program to reflect SL Bio's policies, with decisions made by PubCo's compensation committee. Non-executive independent directors are expected to receive compensation commensurate with duties and experience, including cash retainers, expense reimbursement, and potential equity-based awards under a future equity compensation plan.

Management Comments

• We believe that your background and experience will be a significant asset to the Company, and we look forward to your participation on the Board.

Industry Context

StockSavvy.ai notes that the addition of experienced independent directors, particularly those with cross-border and financial market expertise, is a common practice in SPAC business combinations. This move aims to bolster investor confidence and ensure robust corporate governance for the newly formed public entity, especially given the complexities of US-China transactions and the need for strong financial oversight in emerging growth companies.

Comparison to Industry Standards

• The appointment of independent directors with significant public company and financial experience, such as Joseph Levinson (CPA, former director at Nasdaq-listed AIIO and CLEU) and Qian (Hebe) Xu (investment banking, director at Nasdaq-listed HLP), aligns with best practices for corporate governance in U.S.-listed companies.
• The proposed compensation structure for non-executive independent directors, including cash retainers, expense reimbursement, and equity-based awards, is standard for public companies seeking to attract and retain qualified board members, comparable to practices seen in other SPAC mergers.
• The high beneficial ownership percentage of William Wang (58.9%-59.6%) is notable and suggests strong founder control, which can be higher than typical for mature public companies but is not uncommon in newly public entities formed via SPACs, especially where the target company's founders retain significant equity.

Management Changes

Corporate Governance

Related Party Transactions

• On January 5, 2026, SL Link Co., Ltd., a company controlled by William Wang (anticipated CEO, Director, and Chairman of PubCo), entered into a securities transfer agreement to purchase 30,000 ordinary shares of SL Bio from an individual shareholder at US$66.67 per share.

Stakeholder Impact

• Shareholders (HSPT): Will vote on the business combination and will become shareholders of PubCo. The addition of independent directors may enhance governance and long-term value.
• Shareholders (SL Bio): Will become shareholders of PubCo. The transaction involving SL Link Co., Ltd. impacts the ownership structure.
• Management/Directors: New independent directors are added, and the compensation structure for PubCo's executive officers and non-executive independent directors is outlined.

Next Steps

• The Business Combination Meeting will be held on February 12, 2026, at 9:00 a.m. Eastern Time.
• Shareholders are encouraged to vote as soon as possible if they have not yet done so.
• Following the closing of the Business Combination, PubCo expects to adopt an equity compensation plan for certain independent directors.

Key Dates

Recommendation

This filing is a procedural update to a definitive proxy statement, announcing the addition of two independent director nominees and an update to beneficial ownership. It confirms the business combination process is moving forward as expected without any significant new positive or negative operational or financial news. For investors already holding HSPT, maintaining their position until the business combination is finalized and more substantive operational details of the combined entity are available is prudent. For new investors, waiting for the completion of the merger and the subsequent performance of the combined entity would be advisable.

Keywords

HSPT, SL BIO, SL Science Holding Limited, SPAC, Business Combination, Merger, Director Nominees, Corporate Governance, Beneficial Ownership, SEC Filing, Form 425, Proxy Statement, Nasdaq